| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Maverick Capital · Lee Ainslie | $2.4M | 0.02% | 50.98K | New | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $2.2M | 0.01% | 46.41K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PBH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Byom John EDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Aug 3, 2026 | Clark Clesteen ADirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Aug 3, 2026 | Zier Dawn MDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Aug 3, 2026 | Darecca JamesDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Aug 3, 2026 | Kelly John F.Director | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| May 10, 2026 | Zerillo JeffreyOfficer | Sale at price 52.28 per share. | 351 | $18.35K |
| May 6, 2026 | Zerillo JeffreyOfficer | Sale at price 54.36 per share. | 305 | $16.58K |
| May 4, 2026 | Zerillo JeffreyOfficer | Sale at price 55.32 per share. | 346 | $19.14K |
| May 4, 2026 | Zerillo JeffreyOfficer | Sale at price 54.99 per share. | 1.2K | $66.37K |
| May 3, 2026 | P Pool WilliamGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 7.9K | — |
| May 3, 2026 | Lombardi Ronald MChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 51.1K | — |
| May 3, 2026 | Sacco ChristineChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 19K | — |
| May 3, 2026 | Zerillo JeffreyOfficer | Stock Award(Grant) at price 0.00 per share. | 5.3K | — |
| May 3, 2026 | Mekhail AdelOfficer | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Feb 10, 2026 | Zerillo JeffreyOfficer | Sale at price 65.93 per share. | 1K | $65.93K |
| Jan 5, 2026 | Rosado Jose LuisOfficer | Stock Award(Grant) at price 0.00 per share. | 3.4K | — |
| Nov 30, 2025 | Zerillo JeffreyOfficer | Sale at price 60.00 per share. | 1K | $60.00K |
| Nov 24, 2025 | Byom John EDirector | Sale at price 59.35 per share. | 3K | $178.05K |
| Aug 4, 2025 | Byom John EDirector | Stock Award(Grant) at price 0.00 per share. | 2.1K | — |
| Aug 4, 2025 | Hopkins Sheila ADirector | Stock Award(Grant) at price 0.00 per share. | 2.1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.5 | 7.5 | -14.5 | -5.0 | -15.6 | -0.5 | 6.2 | 3.1 | -11.4 | 6.8 | −20.6% | ||
| 2025 | -1.7 | 10.4 | 1.4 | -5.5 | 5.5 | -6.8 | -7.4 | -8.0 | -8.3 | -2.9 | -1.7 | 3.6 | −21.0% |
| 2024 | 0.5 | 13.1 | 4.3 | -1.1 | -10.4 | 7.1 | 2.8 | 5.4 | -3.4 | 2.3 | 14.9 | -7.9 | +27.6% |
| 2023 | 5.0 | -8.4 | 4.0 | -1.8 | -7.0 | 3.8 | 9.7 | -10.6 | -2.0 | 3.8 | -3.4 | 6.7 | −2.2% |
| 2022 | -6.9 | 5.5 | -11.1 | 3.2 | 2.1 | 5.3 | 2.6 | -16.1 | -1.5 | 9.3 | 12.8 | 1.9 | +3.2% |
| 2021 | 14.7 | 4.3 | 5.7 | -1.2 | 14.5 | 4.5 | 0.9 | 9.2 | -2.2 | 6.9 | -6.7 | 8.4 | +73.9% |
| 2020 | 0.1 | -7.9 | -1.8 | 10.9 | 3.7 | -11.0 | -1.0 | -2.0 | -0.0 | -9.3 | 7.7 | -2.0 | −13.9% |
| 2019 | -9.6 | 4.8 | 2.2 | -1.6 | -1.3 | 9.1 | 9.2 | -7.9 | 8.8 | 2.2 | 6.5 | 7.2 | +31.2% |
| 2018 | -5.8 | -19.2 | -0.2 | -12.7 | 13.6 | 14.8 | -6.9 | 7.8 | -1.6 | -4.6 | 7.4 | -20.5 | −30.5% |
| 2017 | 1.3 | 7.3 | -1.9 | 3.3 | -12.2 | 4.8 | 1.6 | -5.4 | -1.2 | -6.4 | -3.6 | -1.7 | −14.8% |
| 2016 | -9.3 | 4.8 | 9.2 | 6.3 | -4.8 | 2.5 | -3.4 | -10.0 | 0.3 | -6.2 | 5.1 | 9.5 | +1.2% |
| 2015 | -1.3 | 12.5 | 11.3 | -8.5 | 11.9 | 5.3 | 3.0 | -2.3 | -2.9 | 8.5 | 3.8 | 1.2 | +48.3% |
| 2014 | -15.5 | -5.8 | -4.4 | 23.0 | 2.0 | -0.9 | -9.1 | 12.4 | -6.5 | 9.4 | -5.6 | 3.8 | −3.0% |
| 2013 | 7.1 | 10.9 | 8.0 | 4.9 | 9.1 | -0.9 | 16.4 | -4.2 | -7.2 | 3.7 | 12.8 | 1.6 | +78.7% |
| 2012 | 13.9 | 28.5 | 5.9 | -2.8 | -19.2 | 15.1 | 3.8 | -2.1 | 5.6 | 2.5 | 24.2 | -7.3 | +77.7% |
| 2011 | -7.6 | -0.2 | 4.4 | 0.4 | 11.8 | -0.5 | -4.8 | -11.9 | -16.0 | 16.9 | -6.6 | 14.1 | −5.7% |
| 2010 | -1.1 | 3.3 | 12.1 | 7.8 | -20.4 | -8.3 | 16.1 | -10.0 | 33.6 | 8.7 | 9.5 | 1.5 | +52.0% |
| 2009 | -39.8 | -13.9 | -5.3 | 24.7 | -3.6 | -1.3 | 6.2 | 13.5 | -5.0 | -4.0 | 3.1 | 12.8 | −25.5% |
| 2008 | -0.1 | 3.2 | 6.1 | 9.8 | 21.5 | -2.3 | -6.9 | -4.2 | -6.5 | -22.2 | 13.2 | 34.9 | +41.0% |
| 2007 | -2.4 | -9.8 | 3.4 | 9.8 | 1.1 | -1.3 | -3.6 | -12.3 | 0.1 | -4.7 | -19.8 | -10.8 | −42.5% |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Buy / hold / sell counts
No recent headlines.